Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 26, Issue 5, Pages 531-540Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543784.2017.1315406
Keywords
HER2; ErbB2; trastuzumab; gastric cancer; esophageal cancer
Categories
Funding
- NIH [CA-06927, R01 CA188430, K22 CA160725, R21 CA164205]
- Pew Charitable Fund
- Genentech
- State of Pennsylvania
- Bucks County Board of Associates
Ask authors/readers for more resources
Introduction: The blockade of HER2 signaling has significantly improved the outlook for esophagogastric cancer patients. However, targeting HER2 still remains challenging due to complex biology of this receptor in gastric and esophageal cancers.Areas covered: Here, we review complex HER2 biology, current methods of HER2 testing and tumor heterogeneity of gastroesophageal cancer. Ongoing and completed clinical research data are discussed.Expert opinion: HER2 overexpression is a validated target in gastroesophageal cancer, with therapeutic implications resulting in prolonged survival when inhibited in the front-line setting. With standardized HER2 testing in gastro-esophageal cancer, the ongoing trials are testing newer agents and combinations including combination of anti-HER2 antibodies with immunotherapy. Clonal heterogeneity and emergence of resistance will challenge our approach to treating these patients beyond the frontline settings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available